SEC Tracker
Get the app

Oculis Holding OCS

Oculis Holding increases share offering limit to $125M

Securities offering

Form
424B5
Filed
Importance
Routine
  1. Amended Sales Agreement with Leerink Partners
  2. Up to $125,000,000 in ordinary shares offered
  3. Previously sold $61,323,500 in shares
  4. Compensation to Leerink Partners up to 3% of gross proceeds

Written from the 424B5 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Oculis Holding files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float not reported.

  1. Acura Pharmaceuticals ACUR
  2. Ayala Pharmaceuticals ADXS
  3. Ampio Pharmaceuticals AMPE
  4. Alterity Therapeutics ATHE
  5. Adhera Therapeutics ATRX